ArriVent BioPharma, Inc.
AVBP
$20.82
-$0.35-1.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 57.68% | 77.17% | 72.37% | 65.99% | 49.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.44% | 51.37% | 51.33% | 99.12% | 102.11% |
| Operating Income | -26.44% | -51.37% | -51.33% | -99.12% | -102.11% |
| Income Before Tax | -16.09% | -38.35% | -33.85% | -78.72% | -87.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.09% | -38.35% | -33.85% | -78.72% | -87.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.09% | -38.35% | -33.85% | -78.72% | -87.86% |
| EBIT | -26.44% | -51.37% | -51.33% | -99.12% | -102.11% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.34% | 71.21% | 60.98% | 23.88% | -16.17% |
| Normalized Basic EPS | 92.34% | 71.21% | 60.98% | 23.88% | -16.17% |
| EPS Diluted | 92.34% | 71.21% | 60.98% | 23.88% | -16.17% |
| Normalized Diluted EPS | 92.34% | 71.21% | 60.98% | 23.88% | -16.17% |
| Average Basic Shares Outstanding | 1,361.71% | 1,222.06% | 993.08% | 532.22% | 68.53% |
| Average Diluted Shares Outstanding | 1,361.71% | 1,222.06% | 993.08% | 532.22% | 68.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |